Filler composition for chondrocyte differentiation ability and collagen activity, and preparation method therefor
A filler composition combining PLGA, HA, and PDRN microparticles addresses the limitations of existing fillers by enhancing cell adhesion and collagen regeneration, achieving stable collagen activity and effective tissue repair with reduced side effects and extended maintenance period.
Patent Information
- Application Number
- PCT/KR2024/006597
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-15
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current cosmetic fillers based on hydrophobic biodegradable polymers like PLGA, PLLA, and PCL face challenges with slow collagen regeneration due to poor cell adsorption and short decomposition periods, leading to potential side effects such as granulomas and limited long-term tissue repair.
A filler composition comprising PLGA microparticles, hyaluronic acid (HA), and polydeoxyribonucleotide (PDRN) is developed, where the mixture is hydrolyzed and freeze-dried to enhance cell adhesion and collagen production, with a weight ratio of PLGA 70-90%, HA 1-20%, and PDRN 0.1-5%, promoting stable collagen activity and skin regeneration.
The composition increases cell adhesion, maintains collagen activity for over a year, reduces side effects, and effectively supports cartilage cell regeneration and skin repair, with enhanced secretion of growth factors like VEGF and FGF-2, and increased expression of Collagen types I and III.
Smart Images

Figure KR2024006597_21112024_PF_FP_ABST
Abstract
Description
Filler composition for chondrocyte differentiation and collagen activity and method for preparing the same
[0001] The present invention relates to a filler composition for chondrocyte differentiation and collagen activity and a method for producing the same.
[0002] The customer base of the anti-aging industry, which includes functional cosmetics, fillers, botulinum toxin, and beauty services for the skin, is expanding to include the general public, including the middle class. Interest in human cell activation is also increasing due to longevity extension, wellness trends, and advancements in biotechnology.
[0003] The anti-aging industry can be divided into consumer goods, such as cosmetics, which promote cartilage cell activation, the medical sector, and the service sector. The medical sector, in particular, is experiencing growth thanks to the development of numerous related pharmaceuticals and biomaterials, including botulinum toxin and hyaluronic acid fillers.
[0004] Botulinum toxin, which was used to treat strabismus due to its muscle-relaxing effect, is now used for cosmetic purposes in 90% of medical institutions in Korea, and the filler market is also growing rapidly as safe and bio-absorbable pharmaceutical materials such as hyaluronic acid and collagen are commercialized.
[0005] In addition, PDRN promotes the regeneration and growth of bone tissue (Guizzardi et al., Micron, 38, 2007, 722-728) and improves damaged skin repair and wound healing in diabetic animals. This is because it promotes the expression of VEGF (Vascular Endothelial Growth Factor) through a key factor that regulates angiogenesis. PDRN is also effective in skin injuries that make skin regeneration and angiogenesis difficult, such as thermal injury. When PDRN® was administered to deep-dermal second-degree burn injuries, it promoted re-epithelialization and shortened the wound healing time (final wound closure) (Bitto et al., Crit. Care. Med., 36, 2008a, 1594-1602).
[0006] Meanwhile, among fillers for plastic surgery, microparticles made of hydrophobic biodegradable polymers have the advantage of being completely decomposed by hydrolysis in the body and excreted through urine, and can be adjusted to last from as long as 4 years to as short as 6 months depending on the type and molecular weight of the polymer.
[0007] Various filler compositions composed of hydrophobic biodegradable polymers such as Poly-L-Lactic acid (PLLA), Poly-ε-caprolactone (PCL), PLGA (poly(lactic-co-glycolic acid), and polydioxanone (PDO) are being proposed.
[0008] However, PDO has a short degradation period, making it difficult to maintain for a long period of time, while PLGA, PLLA, and PCL have a long degradation period of more than one year, but are known to have side effects such as granuloma due to their high hydrophobic properties.
[0009] In particular, after hydrophobic biodegradable polymer microparticles are injected into the human body, collagen can be regenerated through a foreign body reaction. However, in this process, there is a disadvantage in that collagen regeneration is slow or not done well because cell adsorption to the surface of the hydrophobic biodegradable polymer microparticles is difficult.
[0010] Against this backdrop, the inventors of the present invention conducted extensive research to develop a filler that is advantageous in cell adsorption and has a retention period of more than one year in the body. As a result, they prepared a filler composition in which a mixture of PLGA microparticles, HA, and PDRN was hydrolyzed, and confirmed that the composition increases cell adsorption, has a retention period of more than one year, and promotes skin regeneration, thereby completing the present invention.
[0011] [Prior Art Literature]
[0012] [Patent Document]
[0013] (Patent Document 0001) Republic of Korea Registered Patent No. KR10-1926751
[0014] An object of the present invention is to provide a method for producing a filler composition for molding and cartilage cell regeneration, comprising the steps of: i) producing PLGA microparticles composed of PLGA; ii) providing HA and PDRN microparticles; iii) mixing the PLGA microparticles with HA and PDRN microparticles to produce a mixture; iv) hydrolyzing the mixture; v) dispersing the hydrolyzed mixture in a solution containing a dispersing agent to produce a dispersion; and vi) freeze-drying the dispersion to produce a complex comprising the PLGA microparticles and HA and PDRN microparticles.
[0015] Another object of the present invention is to provide a filler composition for plastic surgery and cartilage cell regeneration manufactured by the above manufacturing method.
[0016] Another object of the present invention is to provide an injection for plastic surgery and cartilage cell regeneration, comprising the filler composition.
[0017] The advantages and features of the present invention, and the methods for achieving them, will become clearer with reference to the embodiments described in detail below together with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below and may be implemented in various different forms. These embodiments are provided solely to ensure that the disclosure of the present invention is complete and to fully inform those skilled in the art of the scope of the present invention, and the present invention is defined solely by the scope of the claims.
[0018] The terminology used herein is for the purpose of describing embodiments only and is not intended to limit the present invention. In this specification, the singular also includes the plural unless specifically stated otherwise. As used herein, the terms "comprises" and / or "comprising" do not exclude the presence or addition of one or more other components in addition to the mentioned components. Like reference numerals refer to like components throughout the specification, and "and / or" includes each and any combination of one or more of the mentioned components. Although "first", "second", etc. are used to describe various components, these components are not limited by these terms. These terms are only used to distinguish one component from another. Therefore, it should be understood that a first component mentioned below may also be a second component within the technical spirit of the present invention.
[0019] Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in their common sense to those skilled in the art to which the present invention pertains. Furthermore, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise.
[0020] The present invention provides a method for producing a filler composition for molding and cartilage cell regeneration, comprising the steps of: i) producing PLGA microparticles composed of PLGA; ii) providing HA and PDRN microparticles; iii) mixing the PLGA microparticles with HA and PDRN microparticles to produce a mixture; iv) hydrolyzing the mixture at 100 to 140°C for 50 to 100 minutes; v) dispersing the hydrolyzed mixture in a solution containing a dispersant to produce a dispersion; and vi) freeze-drying the dispersion to produce a complex comprising the PLGA microparticles and HA and PDRN microparticles.
[0021] The PLGA of the present invention is a poly(lactic-co-glycolic acid) copolymer, which is a biodegradable and biocompatible polymer. The PLGA can be obtained in different polymer forms depending on the ratio of lactide and glycolide, and the crystallinity, glass transition temperature, hydrolysis time, etc. of the PLGA can vary depending on the ratio. The PLGA is non-toxic, can be metabolized and excreted, and has excellent physical properties, so it can be used as a therapeutic device such as an implant or a surgical device.
[0022] The HA of the present invention is hyaluronic acid, a polymer compound defined as a glycosaminoglycan having an unbranched polysaccharide chain formed by the condensation of thousands of disaccharide units, and exhibits high solubility in water. By forming cross-linked hyaluronic acid through a specific cross-linking agent and appropriate operating conditions (temperature, pH, etc.), a molecular framework can be created to maintain the shape and tone of epidermal tissue.
[0023] The PDRN of the present invention is a polydeoxyribonucleotide, a compound containing a DNA complex, i.e., a deoxyribonucleotide polymer, which can be used as an active agent necessary for cell regeneration without side effects and can promote cell differentiation.
[0024] In the method for manufacturing the filler composition of the present invention, the weight ratio of the PLGA microparticles based on the total weight of the mixture in step iii) may be 70 to 90 wt%, and more specifically, 75 to 90%, but is not limited thereto.
[0025] In the above step iii), the weight ratio of the HA based on the total weight of the mixture may be 1 to 20 wt%, more specifically 1 to 5%, but is not limited thereto.
[0026] In the above step iii), the weight ratio of the PDRN microparticles based on the total weight of the mixture may be 0.1 to 5 wt%, and more specifically, 0.01 to 1%, but is not limited thereto.
[0027] In the above step iii), the weight ratio of the HA and PDRN microparticles based on the total weight of the mixture may be 5 to 25 wt%, but is not limited thereto.
[0028] In the total weight of the above mixture, the weight ratio of the PLGA microparticles may be 70 to 90 wt%. Outside the above range, cell adhesion is not stable, collagen production is delayed, and the collagen retention period is short, making it difficult to have a long-term tissue repair effect.
[0029] For example, a filler composition for plastic surgery comprising a mixture of PLGA microparticles and HA and PDRN microparticles can sufficiently exist around the PLGA microparticles when the PLGA microparticles are contained at a weight ratio of 75% and the HA and PDRN microparticles are contained at a maximum of 25% (Fig. 2).
[0030] The dispersant of the present invention is used to disperse a physiologically active substance, and a low-molecular-weight dispersant or a high-molecular-weight dispersant polymer can be applied. The low-molecular-weight dispersant refers to a compound having a weight-average molecular weight of less than 15,000 MW, and the high-molecular-weight dispersant polymer refers to a compound containing repeating covalent bonds between one or more monomers and having a weight-average molecular weight of 15,000 MW or more. The low-molecular-weight dispersant is not particularly limited as long as it is acceptable for pharmaceutical compounds, functional food compounds, functional cosmetic compounds, etc. Specifically, it can be a sugar, a cyclodextrin, an amino acid, an organic acid, or other components, and these can be used alone or in combination of two or more.
[0031] The dispersant of the present invention may be selected from the group consisting of cells, growth factors, peptides, amino acids, proteins, sugars, natural polymers, and combinations thereof, but is not limited thereto.
[0032] The cells and growth factors of the present invention may be one or more cells and growth factors selected from the group consisting of mesenchymal stem cells, induced pluripotent stem cells (iPSCs), fibroblast growth factor (FGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), granulocyte morphogenetic stimulating factor (GCSF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor-BB (PDGF-BB), brain-derived neurotrophic factor (BDNF), and glial cell-derived neurotrophic factor (GDNF).
[0033] The peptides, amino acids and proteins of the present invention may be Alanine, Arginine, Asparagine, Aspartic acid, Cysteine, Glutamine, Glutamic acid, Glycine, Histidine, Isoleucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine or a combination thereof.
[0034] The sugar of the present invention is selected from the group consisting of glucose, mannose, idose, galactose, fucose, ribose, xylose, lactose, sucrose, maltose, trehalose, turanose, raffinose, maltotriose, acarbose, water-soluble cellulose, synthetic cellulose, sugar alcohol, glycerin, sorbitol, lactitol, maltitol, mannitol, xylitol, erythritol, polyol, derivatives thereof, or It could be a combination of these.
[0035] The natural polymer of the present invention may be at least one selected from the group consisting of chitosan, alginate, and combinations thereof, but is not limited thereto.
[0036] In the above step iv), hydrolysis may be performed at 100 to 140°C for 50 to 100 minutes, more specifically at 100 to 130°C for 50 to 90 minutes, but is not limited thereto.
[0037] In the above step vi), the freeze-drying may be performed at a temperature of -90 to -70°C for 10 to 30 hours, and more specifically, may be performed at a temperature of -80 to -70°C for 10 to 20 hours, but is not limited thereto.
[0038] The step of i) providing PLGA microparticles of the present invention may include the step of ii) dissolving PLGA in a solvent to prepare a 1-1 solution; i-ii) dissolving a surfactant in distilled water to prepare a 1-2 solution; i-iii) mixing and stirring the 1-1 solution and the 1-2 solution, and then removing the solvent to prepare a 1-3 solution; and i-iv) precipitating PLGA microparticles in the 1-3 solution and then removing the supernatant to obtain PLGA microparticles.
[0039] In the above step ii), the solvent may be at least one selected from the group consisting of chloroform, acetone, acetonitrile, dioxane, methoxybenzene, dichloromethane, dimethylformamide, dimethylsulfoxide, ethylacetate, hexafluoroisopropanol, and anisole, but is not limited thereto.
[0040] In the above steps i-ii), the surfactant may be PVA (Polyvinyl alcohol), but is not limited thereto.
[0041] After the above steps i-iv), a step iv) of washing the PLGA microparticles may be further included.
[0042] The average size of the PLGA microparticles of the present invention may be 20 to 100 μm, and more specifically, 20 to 70 μm.
[0043] The filler composition of the present invention can be prepared by mixing PLGA and PDO.
[0044] The step of ii) providing HA and PDRN microparticles of the present invention may include a step of preparing a 2-1 solution by dissolving HA and PDRN microparticles in deionized distilled water.
[0045] In addition, the present invention provides a filler composition for molding and cartilage cell regeneration manufactured by the above manufacturing method.
[0046] The filler composition of the present invention can increase the secretion amount of growth factors VEGF and FGF-2, and increase collagen activity by increasing the expression of Collagen type I and Collagen type III.
[0047] The filler composition of the present invention comprises PLGA microparticles, HA, and PDRN microparticles, and may additionally comprise PDO. The filler composition has a lower risk of side effects and higher stability than filler compositions comprising PLLA microparticles or PCL microparticles, increases cell adhesion, has a maintenance period of one year or more, and can promote collagen activation and skin regeneration.
[0048] In addition, the present invention provides an injection for plastic surgery and cartilage cell regeneration comprising the filler composition.
[0049] The injection of the present invention can be used in a form in which it is administered to the skin area of a subject using an injection device having a fine needle or canola shape.
[0050] The above-described injection comprises PLGA microparticles and HA and PDRN microparticles of the present invention, and may further comprise a biocompatible carrier. The biocompatible carrier may comprise at least one selected from the group consisting of alginic acid and salts thereof, carboxymethyl cellulose and salts thereof, dextran and salts thereof, collagen, gelatin, and elastin, but is not limited thereto.
[0051] The injection of the present invention may additionally contain a physiologically active substance, a local anesthetic, water for injection, sterile water or distilled water depending on the intended use.
[0052] The present invention provides a filler composition for chondrocyte differentiation and collagen activity and a method for preparing the same, wherein the composition comprises a mixture of PLGA microparticles and HA and PDRN microparticles, and can be usefully used as a filler composition by stably inducing cell adhesion while increasing collagen production, activating chondrocyte regeneration, and confirming a tissue repair effect.
[0053] Figure 1 is a flow chart showing a method for manufacturing a filler composition for plastic surgery and cartilage cell regeneration.
[0054] Figure 2 is a schematic diagram showing the arrangement structure between PLGA microparticles in a filler composition for plastic surgery and cartilage cell regeneration.
[0055] Figure 3 is a diagram showing a scanning electron microscope (SEM) photograph of PLGA microparticles.
[0056] Figure 4 is a scanning electron microscope (SEM) photograph of a mixture of PDRN and hyaluronic acid.
[0057] Figure 5 is a scanning electron microscope (SEM) image of a mixture of PLGA microparticles, PDRN, and hyaluronic acid.
[0058] Figure 6 is a diagram showing the results of confirming the secretion amounts of VEGF, FGF-2, and BMP-2 to evaluate the in vitro efficacy of human bone marrow-derived mesenchymal stem cells for a mixture of PLGA microparticles, PDRN, and hyaluronic acid.
[0059] Figure 7 is a diagram showing collagen type I and III expression, chondrocyte differentiation potential, and osteogenic differentiation potential to evaluate the in vitro efficacy of human bone marrow-derived mesenchymal stem cells for a mixture of PLGA microparticles, PDRN, and hyaluronic acid.
[0060] Hereinafter, the present invention will be described in more detail through the following examples and experimental examples. However, the scope of the present invention is not limited to the following examples and experimental examples, but includes modifications of technical concepts equivalent thereto.
[0061] Example 1. Preparation of PLGA microparticles
[0062] 2 g of PLGA was dissolved in 50 mL of HFIP (Hexafluoroisopropanol) to prepare Solution 1-1. 2 g of PVA as a surfactant was dissolved in 50 mL of distilled water to prepare Solution 1-2. HFIP was removed by mixing Solutions 1-1 and 1-2 and stirring the resulting mixture at 400 rpm for 3 days, simultaneously obtaining Solution 1-3 containing PLGA microparticles.
[0063] After stirring, the mixture was left to settle for more than 24 hours to allow the polymer microparticles to settle. The supernatant was removed and the PLGA microparticles were isolated. Distilled water was added to the separated PLGA microparticles and stirred again to wash them. This washing step was repeated a total of three times, and PLGA microparticles were manufactured (Fig. 3).
[0064] Example 2. Mixing of PLGA microparticles with HA and PDRN microparticles
[0065] Fine particles were mixed according to Table 1 below, and five types of fine particle mixtures, each weighing a total of 10 g, were prepared.
[0066] [Table 1]
[0067]
[0068] Each was added to a 100 mL solution (15%) containing a dissolved dispersant composition, and stirred for 2 hours to prepare a completely dispersed solution. The dispersion was poured evenly into a hemispherical mold with a diameter of 1 cm or into a cylindrical container, which was then placed in an ultra-low temperature freezer at -75°C to completely freeze for 12 hours.
[0069] Afterwards, a completely dried complex was prepared by freeze-drying. The final complex, in which PLGA: HA+PDRN were mixed in a ratio of 85:15, is as shown in Fig. 5.
[0070] Example 3. High-temperature and high-pressure hydrolysis treatment
[0071] By surface-treating the microparticles (a mixture of PLGA microparticles and HA + PDRN microparticles, which is a mixture presented in Example 2 above) using a high temperature and high pressure device (120°C, 50 minutes), the hydrophilic properties and cell attachment rate were improved through hydrolysis through surface modification of the microparticles.
[0072] Experimental Example 1. In vitro Validation Test
[0073] Using a mixture of PLGA microparticles and HA + PDRN microparticles, cell markers (CD-44, CD-105, Vimentin, and Integrin beta) were analyzed in human bone marrow-derived mesenchymal stem cells (hMSCs) in vitro using flow cytometry, and the secretion of growth factors (VEGF, FGF-2, BMP-2, PDGF-BB, TGF-beta1, and IGF-1) for the test substances was evaluated using ELISA.
[0074] Additionally, the expression of collagen types I and III, chondrocyte differentiation potential, and osteogenic differentiation potential were confirmed by immunofluorescence staining, toluidine blue staining, and Alizarin red staining, respectively.
[0075] As shown in Fig. 6, the test results showed that, when analyzing the growth factor secretion amount based on 100% of the untreated group, VEGF and FGF-2 increased in both the 50 μg / mL and 100 μg / mL concentrations of the test group (a mixture of PLGA microparticles and HA and PDRN microparticles, referred to as the test group hereafter) compared to the untreated group. BMP-2 decreased in both the 50 μg / mL and 100 μg / mL concentrations of the test group compared to the untreated group, but the rate of change was smaller than that of the control group (Fig. 6).
[0076] For collagen type I and collagen type III immunofluorescence staining, expression increased at concentrations of 50 μg / mL and 100 μg / mL in the test group compared to the untreated group. For osteogenic differentiation potential, it was confirmed that it significantly increased at concentrations of 50 μg / mL and 100 μg / mL in the test group compared to the untreated and control groups (Fig. 7).
[0077] This suggests that the mixture of PLGA microparticles and HA and PDRN microparticles is effective in improving the secretion of specific growth factors (VEGF and FGF-2), collagen type I and collagen type III expression, and osteogenic differentiation potential.
[0078] While the embodiments of the present invention have been described above, the present invention is not limited to the above embodiments, but can be manufactured in various different forms. Those skilled in the art will understand that the present invention can be implemented in other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood to be illustrative in all respects and not restrictive.
Claims
1. i) A step of manufacturing PLGA microparticles composed of PLGA (poly(lactic-co-glycolic acid)); ii) a step of providing HA (hyaluronic acid) and PDRN (polydeoxyribonucleotide) microparticles; iii) A step of preparing a mixture by mixing the PLGA microparticles with HA and PDRN microparticles; iv) a step of hydrolyzing the mixture; v) a step of dispersing the hydrolyzed mixture in a solution containing a dispersant to prepare a dispersion; and vi) A method for producing a filler composition for molding or cartilage cell regeneration, comprising the step of producing a complex including the PLGA microparticles and HA and PDRN microparticles by freeze-drying the dispersion.
2. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that the weight ratio of the PLGA microparticles based on the total weight of the mixture in step iii) is 70 to 90 wt%.
3. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that the weight ratio of the HA is 1 to 20 wt% based on the total weight of the mixture in the above step iii).
4. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that the weight ratio of the PDRN microparticles based on the total weight of the mixture in step iii) is 0.01 to 5 wt%.
5. In paragraph 1, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that the dispersant is at least one selected from the group consisting of cells, growth factors, peptides, amino acids, proteins, sugars, and natural polymers.
6. In paragraph 5, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that the natural polymer is at least one selected from the group consisting of chitosan and alginate.
7. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that in the step iv), the hydrolysis is performed at 100 to 140°C for 50 to 100 minutes.
8. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that in the step vi), the freeze-drying is performed at a temperature of -90 to -70°C for 10 to 20 hours.
9. In paragraph 1, A method for producing a filler composition for molding or cartilage cell regeneration, characterized in that in the step i), PLGA microparticles are provided from the steps of: ii) dissolving PLGA in a solvent to prepare a 1-1 solution; i-ii) dissolving a surfactant in distilled water to prepare a 1-2 solution; i-iii) mixing and stirring the 1-1 solution and the 1-2 solution, and then removing the solvent to prepare a 1-3 solution; and i-iv) precipitating PLGA microparticles in the 1-3 solution and then removing the supernatant to obtain PLGA microparticles.
10. In paragraph 9, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that in the step ii), the solvent is at least one selected from the group consisting of chloroform, acetone, acetonitrile, dioxane, methoxybenzene, dichloromethane, dimethylformamide, dimethylsulfoxide, ethyl acetate, hexafluoroisopropanol, and anisole.
11. In paragraph 9, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that in the above step i-ii), the surfactant is PVA (Polyvinyl alcohol).
12. In paragraph 9, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that it further comprises a step of washing the PLGA microparticles iv) after the above steps i-iv).
13. In paragraph 1, A method for producing a filler composition for plastic surgery or cartilage cell regeneration, characterized in that the average size of the PLGA microparticles is 20 to 100 μm.
14. A filler composition for plastic surgery or cartilage cell regeneration manufactured by the manufacturing method of paragraph 1.
15. In paragraph 14, The composition is a filler composition for plastic surgery or cartilage cell regeneration, characterized in that it increases the secretion amount of growth factors VEGF (vascular endothelial growth factor) and FGF-2 (fibroblast growth factor-2).
16. In paragraph 14, A filler composition for plastic surgery or cartilage cell regeneration, characterized in that the composition increases the expression of collagen type I and collagen type III.
17. An injection for plastic surgery or cartilage cell regeneration, comprising the filler composition of Article 14.
Citation Information
Patent Citations
Coated Thread For Dermal Filling And Its Coating Method
KR101926751B1
Wound dressing with chitosan hydrogel and PDRN and a dressing therefor
KR1020180060542A
Fabrication method of hybrid hydrogel, Fabricaltion method of injection comprising the same, and Hybrid hydrogel
KR102094407B1
Hybrid hydrogel injection for dermal filler application based on hyaluronic acid containing biodegradable polymer microparticle and method for preparing the same
KR102403554B1
Biodegradable polymer microsphere with hydrophilic surface using plasma treatment technique and method for preparing the same
KR102403559B1
